08:13 AM EDT, 10/14/2024 (MT Newswires) -- Bausch + Lomb ( BLCO ) said Monday the US Food and Drug Administration has approved its EnVista Envy vision intraocular lenses, which provide a range of vision with dysphotopsia tolerance on its EnVista intraocular platform for eye cataract patients.

The approval followed a clinical trial in which 94% of 332 patients showed little to no difficulty viewing close objects and 93% were "completely to moderately satisfied" with their vision after surgery, the company said.

The company said the lenses, already approved by Health Canada in May, will be available in the US in limited numbers in the next few weeks and available more widely next year.

Price: 21.16, Change: +1.69, Percent Change: +8.68